Skip to Main Content

Rise and shine, another busy day is on the way. And this looks to be a delightfully sunny day as well here on the Pharmalot campus, where the shortest of short people is sleeping in. As for us, we are pursuing the usual routine of juggling meetings, calls, deadlines, and whatnot. No doubt, you may relate. So please join us for a needed cup of stimulation as we dig in. And, of course, here are some tidbits. Have a great day and do keep in touch …

The Drug Controller General of India is inspecting 200 drug makers, including leading manufacturers such as Cipla and Pfizer, for allegedly selling poor-quality medicines and failing to comply with manufacturing standards, the Times of India tells us. This is the first time that inspections on this scale have been undertaken by the regulator and follows ongoing concerns about quality-control problems at Indian facilities.


Meanwhile, the US Food and Drug Administration has banned Phalanx Labs from shipping products to the United States after the Indian company, which makes pharmaceutical ingredients, refused to let inspectors visit its site in Visakhapatnam, InPharma Technologist reports. The refusal suggests the company makes products under insanitary conditions, according to an FDA notice.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!